Dr. Todd Cooper, D.O

NPI: 1205943701
Total Payments
$188,792
2021 Payments
$187,039
Companies
5
Transactions
8

Payment Breakdown by Category

Research$185,417 (98.2%)
Consulting$2,025 (1.1%)
Other$1,082 (0.6%)
Food & Beverage$138.32 (0.1%)
Travel$129.40 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $185,417 2 98.2%
Consulting Fee $2,025 1 1.1%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,082 1 0.6%
Food and Beverage $138.32 3 0.1%
Travel and Lodging $129.40 1 0.1%

Payments by Type

Research
$185,417
2 transactions
General
$3,375
6 transactions

Top Paying Companies

Company Total Records Latest Year
Foundation Medicine, Inc. $185,000 1 $0 (2021)
Janssen Research & Development, LLC $2,025 1 $0 (2021)
Celgene Corporation $1,499 2 $0 (2018)
JAZZ PHARMACEUTICALS INC. $225.78 3 $0 (2021)
E.R. Squibb & Sons, L.L.C. $41.94 1 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2021 $187,039 3 Foundation Medicine, Inc. ($185,000)
2019 $212.17 2 JAZZ PHARMACEUTICALS INC. ($212.17)
2018 $1,082 1 Celgene Corporation ($1,082)
2017 $458.94 2 Celgene Corporation ($417.00)

All Payment Transactions

8 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
10/28/2021 JAZZ PHARMACEUTICALS INC. RYLAZE (Drug), DEFITELIO Food and Beverage In-kind items and services $13.61 General
Category: HEMATOLOGY/ONCOLOGY
06/28/2021 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $2,025.00 General
04/30/2021 Foundation Medicine, Inc. FOUNDATIONONE HEME (Device) In-kind items and services $185,000.00 Research
Study: FoundationOne Heme-AMC-PRO-20-2059 • Category: ONCOLOGY
12/03/2019 JAZZ PHARMACEUTICALS INC. Travel and Lodging Cash or cash equivalent $129.40 General
12/02/2019 JAZZ PHARMACEUTICALS INC. DEFITELIO (Drug) Food and Beverage In-kind items and services $82.77 General
Category: HEMATOLOGY
06/13/2018 Celgene Corporation Revlimid (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program In-kind items and services $1,082.00 General
Category: Hematology / Oncology
12/09/2017 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $41.94 General
10/30/2017 Celgene Corporation Revlimid (Drug) In-kind items and services $417.00 Research
Study: CC-5013-AML-002 • Category: Hematology / Oncology

Research Studies & Clinical Trials

Study Name Company Amount Records
FoundationOne Heme-AMC-PRO-20-2059 Foundation Medicine, Inc. $185,000 1
CC-5013-AML-002 Celgene Corporation $417.00 1

About Dr. Todd Cooper, D.O

Dr. Todd Cooper, D.O is a Pediatric Hematology-Oncology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205943701.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Todd Cooper, D.O has received a total of $188,792 in payments from pharmaceutical and medical device companies, with $187,039 received in 2021. These payments were reported across 8 transactions from 5 companies. The most common payment nature is "" ($185,417).

Practice Information

  • Specialty Pediatric Hematology-Oncology
  • Other Specialties Pediatric Hematology-Oncology
  • Location Birmingham, AL
  • Active Since 08/23/2006
  • Last Updated 12/12/2013
  • Taxonomy Code 2080P0207X
  • Entity Type Individual
  • NPI Number 1205943701

Products in Payments

  • FOUNDATIONONE HEME (Device) $185,000
  • Revlimid (Drug) $1,499
  • DEFITELIO (Drug) $82.77
  • RYLAZE (Drug) $13.61

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Hematology-Oncology Doctors in Birmingham